The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma

Maria Soares; Jorge Correia; José Cabeçadas; Conceição Peleteiro; Fernando Ferreira

The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma

Maria Soares, Jorge Correia, José Cabeçadas, Conceição Peleteiro, Fernando Ferreira

Resultado de pesquisa: ???type-name??? › ???researchoutput.researchoutputtypes.contributiontobookanthology.conference??? › revisão de pares

Resumo

The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.

Idioma original	???core.languages.en_GB???
Título da publicação do anfitrião	Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012
Páginas	9-17
Número de páginas	9
Estado da publicação	???researchoutput.status.published??? - 2012
Publicado externamente	Sim
Evento	1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012 - Vilamoura, Algarve Duração: 1 fev. 2012 → 4 fev. 2012

Série de publicação

Nome	Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012

???event.eventtypes.event.conference???

???event.eventtypes.event.conference???	1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012
País/Território	Portugal
Cidade	Vilamoura, Algarve
Período	1/02/12 → 4/02/12

ODS da ONU

Este resultado contribui para o(s) seguinte(s) Objetivo(s) de Desenvolvimento Sustentável

Outros arquivos e links

Link to publication in Scopus

Citar isto

Soares, M., Correia, J., Cabeçadas, J., Peleteiro, C., & Ferreira, F. (2012). The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. Em Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012 (pp. 9-17). (Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012).

Soares, Maria ; Correia, Jorge ; Cabeçadas, José et al. / The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012. 2012. pp. 9-17 (Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012).

@inproceedings{014739bfa5f846848502a734455387a1,

title = "The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma",

abstract = "The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.",

author = "Maria Soares and Jorge Correia and Jos{\'e} Cabe{\c c}adas and Concei{\c c}{\~a}o Peleteiro and Fernando Ferreira",

year = "2012",

language = "English",

isbn = "9789898425942",

series = "Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012",

pages = "9--17",

booktitle = "Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012",

note = "1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012 ; Conference date: 01-02-2012 Through 04-02-2012",

}

Soares, M, Correia, J, Cabeçadas, J, Peleteiro, C & Ferreira, F 2012, The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. em Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012. Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012, pp. 9-17, 1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012, Vilamoura, Algarve, Portugal, 1/02/12.

The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. / Soares, Maria; Correia, Jorge; Cabeçadas, José et al.
Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012. 2012. p. 9-17 (Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012).

Resultado de pesquisa: ???type-name??? › ???researchoutput.researchoutputtypes.contributiontobookanthology.conference??? › revisão de pares

TY - GEN

T1 - The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma

AU - Soares, Maria

AU - Correia, Jorge

AU - Cabeçadas, José

AU - Peleteiro, Conceição

AU - Ferreira, Fernando

PY - 2012

Y1 - 2012

N2 - The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.

AB - The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.

UR - http://www.scopus.com/inward/record.url?scp=84861972925&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:84861972925

SN - 9789898425942

T3 - Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012

SP - 9

EP - 17

BT - Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012

T2 - 1st International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012

Y2 - 1 February 2012 through 4 February 2012

ER -

Soares M, Correia J, Cabeçadas J, Peleteiro C, Ferreira F. The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma. Em Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012. 2012. p. 9-17. (Proceedings of the International Workshop on Veterinary Biosignals and Biodevices, VBB 2012, in Conjunction with BIOSTEC 2012).

The value of a new cancer biomarker fHER-2 proto-oncogene in the diagnosis of feline mammary carcinoma

Resumo

Série de publicação

???event.eventtypes.event.conference???

ODS da ONU

Outros arquivos e links

Impressão digital

Citar isto